骨髓增生异常综合征患者红细胞输注的真实成本:时间驱动作业成本法研究
该研究在澳大利亚大型大学教学医院前瞻性采用时间驱动作业成本法,观察并流程映射MDS患者红细胞输注全过程,涵盖输血前采血、实验室流程、住院与门诊临床输血、临床随访及输血治理监督。每单位红细胞输注总成本为440.47美元,每患者年估算成本为6607.12美元;医院相关成本占总成本41%,设备占16%、人员占14%;同种免疫使流程成本增加24%。结论提示预算输血总成本时需纳入医院流程成本。
要点
- MDS患者每单位红细胞输注总成本为440.47美元,每患者年估算成本为6607.12美元。
- 医院相关成本占输血总成本41%,其中设备占16%、人员占14%。
- 同种免疫使红细胞输注流程成本增加24%。
核心结论
- MDS患者红细胞输注的真实成本远超血液单位采购成本,每单位总成本为440.47美元,每患者年估算成本为6607.12美元。
- 医院流程成本应纳入输血总成本核算与预算,并为以减少红细胞输注负担为目标的治疗的成本效果评估提供依据。
研究设计与样本
- 在澳大利亚一家大型大学教学医院开展前瞻性时间驱动作业成本法研究。
- 观察并流程映射MDS患者红细胞输注全部相关活动,从输血前采血到实验室流程、住院与门诊临床输血、临床随访及输血治理监督。
主要发现
- 每单位红细胞输注总成本为440.47美元,每患者年估算成本为6607.12美元。
- 医院相关成本占总成本41%,最大贡献为设备(16%),其次为人员(14%)。
- 同种免疫使流程成本增加24%。
关键数值与推荐
- 每单位红细胞输注总成本:440.47美元。
- 每患者年估算成本:6607.12美元。
- 医院相关成本占比41%,设备占16%,人员占14%。
- 同种免疫使流程成本增加24%。
临床怎么用
- 在MDS患者输血预算与资源配置中,应计入医院流程成本而非仅计算血液单位采购成本。
- 评估旨在减少红细胞输注负担、改善生活质量的MDS治疗时,可参考本研究成本数据开展成本效果评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time-driven activity-based costing study at a large Australian university teaching hospital. Every activity relating to RBC transfusion in patients with MDS was observed and process-mapped, ranging from patient pre-transfusion phlebotomy through to laboratory processes, clinical transfusion in inpatient and outpatient wards, clinical follow-up and transfusion governance and oversight. For each activity, detailed data collection was undertaken, including timing of individual steps and recording all consumables, equipment and personnel involved. The total per-unit cost was US$440.47, with an annual per-patient estimated cost of US$6607.12. Hospital-related costs contributed 41% of the total cost, with the largest contributor being equipment (16%) followed by staffing (14%). Alloimmunisation increased process costs by 24%. These findings demonstrate that hospital process costs need to be included when considering and budgeting for the total cost of the transfusion process. Our findings will inform future transfusion-related resourcing and cost-effectiveness evaluations of treatments which aim to reduce RBC transfusion burden and improve quality of life in MDS.
引用
- Mo A, Haysom H, Carrandi A, et al. The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study. Br J Haematol. 2026. PMID: 42167920. doi:10.1111/bjh.70556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。